LIGHT is responsible for the technological backbone of VIPPSTAR, focusing on developing the “Regulatory Sandbox,” a controlled environment for testing AI technologies to ensure compliance with European regulations and ethical standards. LIGHT oversees the design and deployment of AI algorithms integrated into the VIPPSTAR platform, ensuring that these solutions are secure, user-friendly, and ethically aligned with the project’s goals.

Spindox Labs is tasked with developing the VIPPSTAR digital platform, integrating advanced AI algorithms for clinical monitoring. The platform is designed to support personalized rehabilitation interventions, providing adaptive tools for users and clinicians.

KU Leuven is instrumental in designing and validating serious games tailored for children aged 3–12 years with VI. It leads the development of JOYVision, a game-based intervention aimed at improving motor and cognitive skills. Additionally, KU Leuven supervises RCTs to ensure robust evaluation of the therapeutic impact of the games and other digital tools.

ASST-BS leads the implementation of clinical interventions targeting children with VI, focusing on developing and validating rehabilitation protocols. It contributes to the collection of clinical data for the VIPPSTAR-NET network and supports the conduction of randomized controlled trials (RCTs) to assess the efficacy of developed tools and interventions.

UNITN leads the development of digital educational resources, including Massive Open Online Courses (MOOC), aimed at children with VI and their families. The university also oversees pedagogical design, ensuring that resources support personalized coaching and foster social inclusion in educational contexts.

The University of Ioannina contributes to developing AI-driven therapeutic protocols and neurocognitive rehabilitation strategies for children with VI.

UL contributes expertise in participatory design methodologies, collaborating with end users to develop assistive technologies that are inclusive and accessible. It supervises the design of digital interfaces to ensure their usability and effectiveness.

Eodyne focuses on certifying the digital tools developed in VIPPSTAR as CE-marked medical devices. It also implements security and privacy protocols, ensuring safe and effective deployment.

This partner focuses on neuroscientific analysis of visual functions in children with VI, contributing to understanding the neurocognitive impact of rehabilitation. It develops algorithms and assessment tools to monitor the effectiveness of interventions, providing critical insights for refining therapeutic approaches.

VIN manages dissemination activities, engaging directly with visually impaired communities to promote the adoption of VIPPSTAR technologies and outcomes.

The University of Edinburgh supports the development of VIPPSTAR-NET by designing analytical models and clinical registries. It also supervises the processing and analysis of clinical and research data to ensure robust outcomes.

This partner is responsible for implementing clinical trials (G1, G2, and G3) in Moldova, collecting epidemiological data for the VIPPSTAR-NET network, and validating therapeutic tools in local contexts.

ISS ensures compliance with European ethical and regulatory standards, coordinating the design and execution of multinational clinical trials. It also oversees data protection measures in alignment with GDPR.

ComfTech designs and develops wearable biomedical devices to monitor physiological parameters. These devices are integrated into rehabilitation protocols, enabling remote monitoring and enhancing the quality of tele-rehabilitation.

This organization designs physical activity programs tailored for children with VI, focusing on enhancing resilience, self-confidence, and body image.

UniBS serves as the project’s central management hub, overseeing administrative, scientific, and operational aspects. It coordinates all consortium activities, ensuring compliance with project timelines and milestones. UniBS supervises the clinical studies for early rehabilitation protocols targeting children aged 0–3 years. It also leads the development and implementation of telemedicine tools for home-based rehabilitation, fostering innovation in early intervention for visual impairments (VI).

Erasmus Medical Center develops advanced metrics for evaluating visual rehabilitation. It employs eye-tracking technologies to monitor and analyze intervention outcomes.

HMS provides scientific and methodological expertise, contributing to the validation of therapeutic technologies and ensuring adherence to evidence-based practices.

Les Glénans promotes sports activities to improve the physical and social well-being of children with VI, fostering their integration into broader social environments.